Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

September 14, 2021

NanoViricides completes licensing of TheraCour anti-COVID drugs

IMAGE | Pixabay.com
By Liese Klein

Shelton’s NanoViricides has licensed a set of drugs that show promise against COVID-19 from West Haven’s TheraCour Pharma, NanoViricides announced Tuesday.

The licensed drugs include antiviral treatments for the SARS-CoV-2 virus and its variants which have caused the recent pandemic. 

NanoViricides signed a memorandum of understanding with TheraCour for limited, exclusive license to research and development toward human testing on antiviral treatments for COVID-19. The transaction was completed this week.

TheraCour Pharma, Inc. and its affiliate, AllExcel, Inc., developed the polymeric micelle nanomedicine technologies used in NanoViricides’ COVID-19 drug candidates.

NanoViricides agreed to pay to TheraCour 15% of net sales of licensed products plus milestone payments including $1.5 million after the initiation of Phase I clinical trials.

In March, NanoViricides announced that two of its COVID-19 drug candidates had been “highly effective” against the virus in pre-clinical laboratory studies.

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF